PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-2516

  1. 358 Posts.
    lightbulb Created with Sketch. 47
    Hello Ceviche, Very good point you made.
    I was against US listing before, but I like your suggestion for Depository Receipts now, as I think the time is right.
    It will cost a bit, but the return will be very quick as the action is going to be in the northern hemisphere's huge OA market.
    We've recommenced the suspended 008 trial and proceeding with the large phase 3 trial in the US. The publicity alone. associated with that will increase the PAR profile enormously.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.